Figures and Tables

From the following article:

Protein therapeutics: new applications for pharmacogenetics

Cecile Krejsa, Mark Rogge & Wolfgang Sadee

Nature Reviews Drug Discovery 5, 507-521 (June 2006)

doi:10.1038/nrd2039

Figure 1 - Protein therapeutics: new applications for pharmacogenetics

Figure 1

Time elapsed between FDA approval and first peer-reviewed publication of pharmacogenetic association.

Table 1 - Protein therapeutics: new applications for pharmacogenetics

Table 1

Pharmacogenetic studies of protein therapeutics — target variations

Table 2 - Protein therapeutics: new applications for pharmacogenetics

Table 2

Pharmacogenetic studies of TNF antagonists I: etanercept in rheumatoid arthritis

Table 3 - Protein therapeutics: new applications for pharmacogenetics

Table 3

Pharmacogenetic studies of TNF antagonists II: infliximab

Table 4 - Protein therapeutics: new applications for pharmacogenetics

Table 4

Pharmacogenetic studies of protein therapeutics: upstream factors

Table 5 - Protein therapeutics: new applications for pharmacogenetics

Table 5

Pharmacogenetic studies of downstream effectors I: interferons

Table 6 - Protein therapeutics: new applications for pharmacogenetics

Table 6

Pharmacogenetic studies of downstream effectors II: monoclonal antibodies